PreveCeutical Medical Inc.
PRVCF
$0.015
-$0.0009-5.66%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 152.00K | 166.30K | 79.90K | 231.50K | 83.50K |
| Depreciation & Amortization | 1.90K | 1.80K | 1.90K | 1.80K | 1.80K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 168.90K | 183.10K | 96.80K | 251.00K | 106.20K |
| Operating Income | -168.90K | -183.10K | -96.80K | -251.00K | -106.20K |
| Income Before Tax | -246.20K | -264.50K | -174.60K | -311.00K | -178.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -246.20K | -264.50K | -174.60K | -311.00K | -178.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -246.20K | -264.50K | -174.60K | -311.00K | -178.70K |
| EBIT | -168.90K | -183.10K | -96.80K | -251.00K | -106.20K |
| EBITDA | -167.00K | -181.30K | -95.00K | -249.20K | -104.40K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 536.94M | 536.94M | 535.30M | 535.30M | 535.30M |
| Average Diluted Shares Outstanding | 536.94M | 536.94M | 535.30M | 535.30M | 535.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
